Show simple item record

dc.contributor.authorPantziarka, Panen_US
dc.contributor.authorSukhatme, Vidulaen_US
dc.contributor.authorBouche, Gauthieren_US
dc.contributor.authorMeheus, Lydieen_US
dc.contributor.authorSukhatme, Vikas Pen_US
dc.date.accessioned2015-05-04T15:27:54Z
dc.date.issued2015en_US
dc.identifier.citationPantziarka, Pan, Vidula Sukhatme, Gauthier Bouche, Lydie Meheus, and Vikas P Sukhatme. 2015. “Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent.” ecancermedicalscience 9 (1): 521. doi:10.3332/ecancer.2015.521. http://dx.doi.org/10.3332/ecancer.2015.521.en
dc.identifier.issn1754-6605en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:15035020
dc.description.abstractItraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti- cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper.en
dc.language.isoen_USen
dc.publisherCancer Intelligenceen
dc.relation.isversionofdoi:10.3332/ecancer.2015.521en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406527/pdf/en
dash.licenseLAAen_US
dc.subjectdrug repurposingen
dc.subjectitraconazoleen
dc.subjecthedgehog pathway inhibitionen
dc.subjectReDO projecten
dc.titleRepurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agenten
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalecancermedicalscienceen
dash.depositing.authorSukhatme, Vikas Pen_US
dc.date.available2015-05-04T15:27:54Z
dc.identifier.doi10.3332/ecancer.2015.521*
dash.authorsorderedfalse
dash.contributor.affiliatedSukhatme, Vikas


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record